- Home
- OMER vs ECAT Comparison
OMER vs ECAT Comparison
Compare OMER & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | ECAT |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMER | ECAT |
|---|---|---|
| Price | $18.37 | $13.51 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $27.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 533.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.20% |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.59 | N/A |
| P/E Ratio | $24.20 | ★ $6.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.24 | $12.99 |
| 52 Week High | $21.24 | $16.51 |
Technical Indicators
Market Signals| Indicator | OMER | ECAT |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 44.16 |
| Support Level | $18.01 | $13.42 |
| Resistance Level | $19.81 | $15.78 |
| Average True Range (ATR) | 0.91 | 0.28 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 63.02 | 48.86 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.